Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone

P. P. Feuillan, C. M. Foster, O. H. Pescovitz, K. D. Hench, T. Shawker, A. Dwyer, J. D. Malley, K. Barnes, Donald (Lynn) Loriaux, G. B. Cutler

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

The McCune-Albright syndrome is characterized by cafe au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P

Original languageEnglish (US)
Pages (from-to)1115-1119
Number of pages5
JournalNew England Journal of Medicine
Volume315
Issue number18
Publication statusPublished - 1986
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feuillan, P. P., Foster, C. M., Pescovitz, O. H., Hench, K. D., Shawker, T., Dwyer, A., ... Cutler, G. B. (1986). Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. New England Journal of Medicine, 315(18), 1115-1119.